Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07632872
PHASE2

Desloratadine as Adjunct Therapy for Rheumatoid Arthritis

Sponsor: Horus University

View on ClinicalTrials.gov

Summary

Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease. The purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment. The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.

Official title: Effect of Desloratadine as Add-On Therapy in Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-05-23

Completion Date

2027-01

Last Updated

2026-06-08

Healthy Volunteers

No

Interventions

DRUG

Desloratadine 5 mg

Desloratadine administered orally as add on therapy to standard disease modifying antirheumatic drugs.

DRUG

Placebo

Matching placebo administered orally as add on therapy to standard disease modifying antirheumatic drugs.

Locations (1)

Faculty of medicine, Mansoura University

Al Mansurah, Egypt